Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: A multi-institutional study

Niibe, Yuzuru; Kazumoto, Tomoko; Toita, Takafumi; Yamazaki, Hideya; Higuchi, Keiko; Noriko,; Suzuki, Kazunori; Umemura, Takashi; Tokumaru, Sunao; Takayama, Makoto; Sekiguchi, Kenji; Matsumoto, Yasuo; Michimoto, Koichi; Oguchi, Masahiko; Hayakawa, Kazushige

doi:10.1016/j.ygyno.2006.03.034

Cited by 54 publications

(51 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, Shirato et al [52] found that half of the patients with recurrent disease detected on serial SCC measurements were candidates for salvage treatment with curative intent. Some authors suggested the use of serum SCC assay, in addition to CT scan or MR imaging, in the followup of patients with advanced disease and elevated antigen level at the time of diagnosis [53]. An isolated para-aortic recurrence can occur in 2.1-3.6% of cervical cancer patients, being more common in those with advanced disease, and some of these can survive for a long period after salvage radiotherapy or chemo-radiation [53][54][55][56][57][58].…”

Section: Serum Scc Assay In the Monitoring Of Response To Treatment Amentioning

confidence: 99%

“…Some authors suggested the use of serum SCC assay, in addition to CT scan or MR imaging, in the followup of patients with advanced disease and elevated antigen level at the time of diagnosis [53]. An isolated para-aortic recurrence can occur in 2.1-3.6% of cervical cancer patients, being more common in those with advanced disease, and some of these can survive for a long period after salvage radiotherapy or chemo-radiation [53][54][55][56][57][58]. About one-third of patients have symptoms at relapse, mainly represented by lumbago or lower extremity oedema, which are associated with a worse prognosis [53].…”

Section: Serum Scc Assay In the Monitoring Of Response To Treatment Amentioning

confidence: 99%

“…An isolated para-aortic recurrence can occur in 2.1-3.6% of cervical cancer patients, being more common in those with advanced disease, and some of these can survive for a long period after salvage radiotherapy or chemo-radiation [53][54][55][56][57][58]. About one-third of patients have symptoms at relapse, mainly represented by lumbago or lower extremity oedema, which are associated with a worse prognosis [53]. For instance Chou et al [54] reported that, among patients with isolated para-aortic relapse after definitive irradiation, 7 of the 12 asymptomatic patients were free of disease after concurrent cisplatin and radiotherapy compared to none of the 14 symptomatic patients.…”

Section: Serum Scc Assay In the Monitoring Of Response To Treatment Amentioning

confidence: 99%

“…For instance Chou et al [54] reported that, among patients with isolated para-aortic relapse after definitive irradiation, 7 of the 12 asymptomatic patients were free of disease after concurrent cisplatin and radiotherapy compared to none of the 14 symptomatic patients. In a retrospective investigation on 67 cervical cancer patients who developed an isolated para-aortic recurrence, Niibe et al [53] found that mean SCC levels were 17.3 ng/dl (range, 0.5-100 ng/dl) at the time of initial treatment and 9.5 ng/dl (range, 0-120 ng/dl) at the time of recurrence (p = 0.01) and that serum SCC > 10 ng/dl at the time of relapse was significantly related to coexisting symptoms (p = 0.05).…”

Section: Serum Scc Assay In the Monitoring Of Response To Treatment Amentioning

confidence: 99%

See 3 more Smart Citations

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

Gadducci

Tana

Cosio

et al. 2008

Critical Reviews in Oncology/Hematology

138

127

View full text Add to dashboard Cite

Section: Serum Scc Assay In the Monitoring Of Response To Treatment Amentioning

confidence: 99%

Section: Serum Scc Assay In the Monitoring Of Response To Treatment Amentioning

confidence: 99%

Section: Serum Scc Assay In the Monitoring Of Response To Treatment Amentioning

confidence: 99%

Section: Serum Scc Assay In the Monitoring Of Response To Treatment Amentioning

confidence: 99%

See 2 more Smart Citations

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

Gadducci

Tana

Cosio

et al. 2008

Critical Reviews in Oncology/Hematology

138

127

View full text Add to dashboard Cite

“…New term "oligo-recurrence" was proposed by Niibe Y et al in 2006 [6]. He proposed the following conditions of the oligo-recurrence: one to several distant metastases, controlled primary site of the cancer and no presence of other distant metastases [6].…”

mentioning

confidence: 99%

CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.

Napieralska¹,

Miszczyk²,

Stąpór-Fudzińska³

2016

neo

View full text Add to dashboard Cite

The aim of the study was to evaluate the effectiveness and toxicity of CyberKnife (CK) stereotactic radiosurgery (SRS) and stereotactic ablative radiation therapy (SABR) of patients with prostate cancer bone metastases. Analysis of prognostic and predictive factors was also performed.Material consisted of 51 patients with 71 bone oligometastases treated using CK SRS/SABR. In half of the patients single lesion was treated, in half 2-5 lesions. Median PSA concentration at the time of metastasis detection was 5.75 ng/ml. Total dose of 6-45Gy (median 20) was delivered with 1-5 fractions of 6-15 Gy (median 9). Biologic equivalent dose (BED) (α/ β=1.6) over 100 Gy was delivered to 45 lesions (63%) in 38 patients (75%).In statistical analysis Kaplan-Meier method, log-rank test and the Cox proportional hazard model were used. One-, two-and three-year overall survival (OS) was 90%, 76% and 70%, respectively. All patients having PSA concentration lower that 1 ng/ml at last control lived at least three years. One-, two-and three-year local control (LC) was 97%, 70% and 30%. Patients with PSA below 20 ng/ml at the time of metastasis detection had better local control of lesions and lower PSA at the last control. Median of PSA concentration after CK based SRS/SABR remains stable during first 12 months of follow-up, dropped during the next months and at last control was comparable to initial level. Median PSA at last control in patients without disease progression was 1.67ng/ml and 20 patients had PSA below 1.0ng/ml. At the last control 59% of patients had no other metastases. Rapid pain decrease was observed in analysed group and during each control about 90% of patients had pain relief. No major toxicity was observed, 3 patients suffered from fracture of irradiated bone. SRS/SABR of prostate cancer bone oligometastases provides good LC of lesions, excellent pain control without additional toxicity. Patients with PSA concentration below 20ng/ml at the time of metastasis detection have better LC and PSA concentration response.

show abstract

Comparison of local therapy in patients with lung oligo‐recurrence of non‐small‐cell lung cancer

Sonoda

Matsuura

Kondo

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives: The effectiveness of local therapy has been reported in non-small-cell lung cancer (NSCLC) patients with oligo-recurrence. However, there is still no clear consensus on the choice of local therapy. We aimed to examine the choice of local therapy in NSCLC patients with lung oligo-recurrence.Methods: Among 1760 consecutive NSCLC patients who underwent complete resection between 1990 and 2008, 535 patients developed recurrence. Lung oligorecurrence was defined as 1-5 metachronous recurrences limited to the lungs only; such recurrence was found in 97 patients. We examined the differences in the prognosis of each therapy for these patients. Results:The 5-year postrecurrence survival (PRS) rates in patients who underwent local therapy (n = 54) and those who did not (n = 43) were 55.6% and 31.1%, respectively; it was significantly higher in patients who underwent local therapy (p = 0.004). Among 47 patients who underwent resection or radiation therapy, the 5-year PRS rates were 61.5% and 47.6% (p = 0.258), and the 5-year postrecurrence progression-free survival rates were 30.3% and 24.7% (p = 0.665), respectively, without any significant difference. Conclusions: Patients with lung oligo-recurrence should consider local therapy individually, depending on their general condition.

show abstract

Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: A multi-institutional study

Cited by 54 publications

References 8 publications

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.

Comparison of local therapy in patients with lung oligo‐recurrence of non‐small‐cell lung cancer

Contact Info

Product

Resources

About